William (Dongfang) Shi, Ph.D.
       Founder, CEO & Chairman



· 
Ph.D. in Medicinal chemistry from University of Nottingham in 1995, and Post- docotra at UT Austin
·  Former Senior Director at Genelabs Technologies Inc and Metabolex Inc.
·  CEO, Chairman and co-founder of Jiangsu Atom Bioscience and Pharmaceutical Co. Ltd
·  27 years for discovering and developing new drug to treat gout, cancer, diabetes and HCV



         Marc Gurwith
,M.D. & J.D.
         CMO



·  B.S. from Yale University
·  M.D. from Harvard University School of Medicine
·  Internal Medicine/Infectious Diseases from Stanford University School of Medicine
·  Former CMO and Senior Vice President at Genelabs, PaxVax, VaxGen, Wyeth Ayerst, and etc.
·  34 years for global clinical research from Phase I to Phase III


      
       Hong Farling
,Ph.D.
       Senior Director of Clinical Operation



·  Ph.D. in Biochemistry from State University of New York, and Post-docotral at Albert Einstein College of Medicine
·  Former Director and Senior Director of Clinical Operations at Vaxart, Portola, KangLaiTe, IMDZ and etc.
·  28 years in US Pharmaceutical companies and 19 years for clinical research and operations




       Roy J. Wu, MBA
      
Senior Vice President of Global Business Development


·  B.S. in Biology from University of San Francisco
·  MBA in International Finance from University of San Francisco School of Business
·  Former Director of Business Development at Quintiles-BRI Inc.
·  Former Vice President and Senior Vice President of Business Development at Novabay Pharmaceuticals Inc., Genelabs Technologies Inc., and Kissei Pharma Inc.
·  
35 years in the pharmaceutical industry with increasingly responsible management positions in Business Development, Licensing, Distributor Management, Interational Marketing, Project Management, Clinical Development, Pacific Sector Regulatory and Pharmaceutical Development
·  Over $160 million raised with 33 projects through equity financing activities, research collaboration and license agreements



     
Adam (Wenqing) Jin, M.S.
     Vice President of Business Development



·  M.S. in Pharmaceutical Manufacturing & Regulatory Affairs from Stevens Institute of Technology
·  Former Project Manager at Sterile Technology LLC, responsible for Process development, GMP validation and Operation
 consulting
·  Responsible for project collaboration, equity financing activities, and license agreements at Atom Bioscience
·  Completed 2 rounds of financing (Round A and A+)
·  Member of board of directors since June 2015



      
Danielle Armas, M.D.
       Senior Principal Investigator



·  M.D. from Myo Clinic College of Medicine
·  Clinical Assistant Professor at University of Arizona, College of Medicine
·  8 years in Principal Investigator, Principal Investigator II and Senior Principal Investigator at Celerion



     
Andrea Stukel
      Clinical Operations Manager



·  B.S. in Biochemsitry from Arizona State University
·  12 years in positions at at MDS Pharma Services and Celerion, Associate Director of Clinical Opreation, Senior Clinical Study Manager, and Director of Global Project Management



     
Changjin Fu, M.S.
      Director of Chemistry


·  M.S. in Chemical Synthesis from University of Yunnan
·  More than 14 years of chemical synthesis and management experince
·  Former Director and Investigator of R&D department in WuXi AppTec, Radiant Pharma & Tech, and Kaihui Pharma



     
Xi Cheng, M.S.
     Director of Biology



·  M.S. in Biology from University of Jiangsu
·  More than 13 years’ experience in Project Management and non-clinical studies
·  Former Senior Investigator at Jiangsu Yew pharmaceutical and Shanghai Rongsheng Biotech Inc.